JOHNSON & JOHNSON - Q2 2019 holdings

 Value Shares↓ Weighting
No holdings reported for quarter Q2 2019
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LEGEND BIOTECH CORPORATION12Q2 202425.6%
FATE THERAPEUTICS, INC.12Q2 202424.8%
PROTAGONIST THERAPEUTICS INC.12Q2 202421.2%
CVRX, INC.12Q2 202419.5%
MEIRAGTX HOLDINGS PLC12Q2 202413.9%
Arrowhead Pharmaceuticals, Inc.12Q2 202424.6%
PROCEPT BIOROBOTICS CORPORATION12Q2 202410.5%
ADICET BIO, INC.12Q2 20243.0%
VOR BIOPHARMA, INC.12Q2 20242.1%
ALDEYRA THERAPEUTICS, INC.12Q2 20241.3%

View JOHNSON & JOHNSON's complete holdings history.

Latest significant ownerships (13-D/G)
JOHNSON & JOHNSON Q2 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Kenvue Inc.May 20, 2024? ?
Contineum Therapeutics, Inc.April 10, 20241,979,17310.7%
BiomX Inc.February 02, 20242,113,4024.6%
CVRx, Inc.February 02, 20244,109,33619.2%
Nanobiotix S.A.February 02, 20245,623,81611.9%
Fusion Pharmaceuticals Inc.January 27, 20233,670,5168.2%
Protagonist Therapeutics, IncJanuary 11, 20232,449,1835.0%
MeiraGTx Holdings plcNovember 14, 20226,641,06413.7%
PhaseBio Pharmaceuticals IncFebruary 01, 20221,607,0443.3%
Provention Bio, Inc.January 17, 20201,124,9732.4%

View JOHNSON & JOHNSON's complete significant-ownership history.

Latest filings
TypeFiled
42024-09-12
42024-09-12
8-K2024-09-10
42024-09-03
1442024-08-30
N-PX2024-08-29
8-K2024-08-26
13F-HR2024-08-09
SC 13G2024-07-30
10-Q2024-07-25

View JOHNSON & JOHNSON's complete filings history.

Compare quarters

Export JOHNSON & JOHNSON's holdings